Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2 amplified and TP53 wild-type glioblastomas

RATIONALE: p53 pathway alterations are key molecular events in glioblastoma (GBM). MDM2 inhibitors increase expression and stability of p53 and are presumed to be most efficacious in patients with TP53 wild-type and MDM2-amplified cancers. However, this biomarker hypothesis has not been tested in pa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Verreault, Maite, Schmitt, Charlotte, Goldwirt, Lauriane, Pelton, Kristine, Haidar, Samer, Levasseur, Camille, Guehennec, Jeremy, Knoff, David, Labussiere, Marianne, Marie, Yannick, Ligon, Azra H., Mokhtari, Karima, Hoang-Xuan, Khe, Sanson, Marc, Alexander, Brian M, Wen, Patrick Y., Delattre, Jean-Yves, Ligon, Keith L., Idbaih, Ahmed
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4842012/
https://ncbi.nlm.nih.gov/pubmed/26482041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1015
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller